Smith & Wesson Brands Shares Slip in Early Trading
The shares of Smith & Wesson Brands Inc. (ticker SWBI) experienced a decline of 4.46 % during the first trading session of the week, closing at USD 13.71 as of 09:12 AM Central Europe on Monday, 26 November 2026. The daily trading volume for the stock was USD 9.5 million, reflecting a moderate level of investor activity in a market that has seen a modest downturn over the past month.
Current Market Snapshot
| Metric | Value |
|---|---|
| Current Share Price | USD 13.71 |
| Market Capitalisation | USD 614.8 million |
| Shares Outstanding | 44.8 million |
| 24‑hour Volume | USD 9.5 million |
| Simple Moving Average (200 days) | USD 13.92 |
| 52‑Week High | USD 17.56 (18 June 2026) |
| 52‑Week Low | USD 8.14 (20 November 2025) |
Smith & Wesson Brands, listed on the Nasdaq, has been trading 2.63 % lower than its position at the close of the previous month. The stock’s recent movement sits below its 200‑day simple moving average, suggesting a short‑term bearish bias that may persist until further corporate or macroeconomic catalysts surface.
Contextualising the Decline
The decline in Smith & Wesson’s stock price follows a pattern observed in the broader portfolio of firms in the firearms and security sector. While the company’s core business—designing and manufacturing a range of firearms, including pistols, revolvers, rifles, and related accessories—remains robust, the sector has faced increasing scrutiny and regulatory pressure. Investors may be pricing in potential future constraints on sales or increased compliance costs, which could impact profitability.
Comparative Performance of Peer Stocks
A quick look at the recent performance of comparable companies provides additional context:
| Company | Recent % Change | Current Price | Market Cap (USD million) | P/E Ratio |
|---|---|---|---|---|
| Natural Grocers By Vitamin C (NGVC) | –2.81 % | USD 31.46 | 725 | 15.22 |
| Cytek Biosciences (CTKB) | +2.95 % | USD 5.59 | 726.6 | – |
| Hertz Global (HTZ) | –6.42 % | USD 2.04 | 727.2 | – |
| Yext (YEXT) | +0.14 % | USD 7.35 | 727.5 | 44.41 |
The relative underperformance of Smith & Wesson against peers such as Cytek Biosciences and Yext underscores the sensitivity of the firearms industry to external factors such as legislative changes, public sentiment, and commodity price fluctuations. In contrast, Cytek’s uptick may reflect its positioning in the rapidly expanding genomics and biotechnology arena, a sector that typically commands higher valuation multiples.
Investor Takeaways
- Short‑term Volatility – The stock’s price is currently trading below its 200‑day moving average, a technical signal that could precede a continuation of the downward trend.
- Sector‑Specific Risks – Potential regulatory shifts, especially in the United States, could further weigh on the company’s earnings prospects.
- Diversification – For investors looking to mitigate sector‑specific risks, diversifying into companies with more stable or growing fundamentals, such as those in biotechnology or consumer services, may be prudent.
Company Overview
Smith & Wesson Brands Inc., headquartered in the United States, specializes in the manufacturing of firearms and related accessories for consumers, law enforcement, and security agencies. The firm’s product line includes pistols, revolvers, rifles, handcuffs, and various accessories. Smith & Wesson’s inaugural public offering was on November 4 , 1998, and the company is listed on the Nasdaq exchange. Additional information can be accessed through the firm’s website at www.smith-wesson.com .
Note: All figures are based on the most recent trading data available at the time of writing and are subject to change as the market evolves.
